LEIDEN, THE NETHERLANDS -- (MARKET WIRE) -- April 25, 2007 -- OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery and development company, announces today that it reached agreement with IsoTis, Inc. (NASDAQ: ISOT) to obtain additional rights to its PolyActive™ drug delivery technology, the technology used in OctoPlus' lead product Locteron™. Locteron is a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, currently in Phase IIa studies.
